1. Protein arginine methyltransferases and hepatocellular carcinoma: A review
   Yu Lei et al, 2021, Translational Oncology CrossRef
2. Chemoinformatic Catalyst Selection Methods for the Optimization of Copper–Bis(oxazoline)-Mediated, Asymmetric, Vinylogous Mukaiyama Aldol Reactions
   Casey L. Olen et al, 2024, ACS Catalysis CrossRef
3. Glioblastoma with PRMT5 gene upregulation is a key target for tumor cell regression
   Maher Kurdi et al, 2024, Oncologie CrossRef
4. Myelocytomatosis‐Protein Arginine N‐Methyltransferase 5 Axis Defines the Tumorigenesis and Immune Response in Hepatocellular Carcinoma
   Yuhong Luo et al, 2021, Hepatology CrossRef
5. Novel oncogenes and tumor suppressor genes in hepatocellular carcinoma
   Fang Wang et al, 2021, Liver Research CrossRef
6. Recent advances in molecular biomarkers for patients with hepatocellular carcinoma
   Shinichi Umeda et al, 2019, Expert Review of Molecular Diagnostics CrossRef
7. Protein Arginine Methyltransferase 5 (PRMT5) Inhibitors in Oncology Clinical Trials: A review
   Kavanya Feustel et al, 2022, Journal of Immunotherapy and Precision Oncology CrossRef
8. Discovery of First-in-Class Protein Arginine Methyltransferase 5 (PRMT5) Degraders
   Yudao Shen et al, 2020, Journal of Medicinal Chemistry CrossRef
9. The Role of the PRMT5–SND1 Axis in Hepatocellular Carcinoma
   Tanner Wright et al, 2021, Epigenomes CrossRef
10. PRMT5: An Emerging Target for Pancreatic Adenocarcinoma
    Michael K. C. Lee et al, 2021, Cancers CrossRef
11. High PRMT5 expression is associated with poor overall survival and tumor progression in bladder cancer
    Lei Tan et al, 2020, Aging CrossRef
12. Host Epigenetic Alterations and Hepatitis B Virus-Associated Hepatocellular Carcinoma
    Mirjam B. Zeisel et al, 2021, Journal of Clinical Medicine CrossRef
13. Curcumin ameliorates PRMT5-MEP50 arginine methyltransferase expression by decreasing the Sp1 and NF-YA transcription factors in the A549 and MCF-7 cells
    Biji Chatterjee et al, 2019, Molecular and Cellular Biochemistry CrossRef
14. The Structure and Functions of PRMT5 in Human Diseases
    Aishat Motolani et al, 2021, Life CrossRef
15. Nuclear to cytoplasmic transport is a druggable dependency in MYC-driven hepatocellular carcinoma
    Anja Deutzmann et al, 2024, Nature Communications CrossRef
16. An integrated multigene expression panel to predict long-term survival after curative hepatectomy in patients with hepatocellular carcinoma
    Mitsuro Kanda et al, 2017, Oncotarget CrossRef
17. Discovery of cysteine-targeting covalent histone methyltransferase inhibitors
    Yifan Zhao et al, 2023, European Journal of Medicinal Chemistry CrossRef
18. Protein Arginine Methyltransferase 5 Functions via Interacting Proteins
    Zhenzhen Liang et al, 2021, Frontiers in Cell and Developmental Biology CrossRef
19. Ribavirin inhibits cell proliferation and metastasis and prolongs survival in soft tissue sarcomas by downregulating both protein arginine methyltransferases 1 and 5
    Qingqing Zhang et al, 2022, Basic & Clinical Pharmacology & Toxicology CrossRef
20. Role of protein arginine methyltransferase 5 in human cancers
    Wendi Xiao et al, 2019, Biomedicine & Pharmacotherapy CrossRef
21. Hepatic metastasis of gastric cancer is associated with enhanced expression of ethanolamine kinase 2 via the p53–Bcl-2 intrinsic apoptosis pathway
    Takashi Miwa et al, 2021, British Journal of Cancer CrossRef
22. Clinicopathological and Prognostic Significance of PRMT5 in Cancers: A System Review and Meta-Analysis
    Zhenzhen Liang et al, 2021, Cancer Control CrossRef
23. Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Advanced Solid Tumors
    Maria Vieito et al, 2023, Clinical Cancer Research CrossRef